Table 2. Antiviral Treatment Rates in Privately Insured Patients With CHB Diagnosis^a.

Subgroup	Patients With CHB Diagnosis, No.	Patients Receiving Treatment, No.	Treatment Rate Among Patients With CHB Diagnosis, % (95% CI)	P Value
Overall	57 847	17 734	30.66 (30.28-31.03)
Age group, y
6-17	711	94	13.22 (10.73-15.71)	<.001
18-34	11 519	3298	28.63 (27.81-29.46)
35-44	15 837	4958	31.31 (30.58-32.03)
45-54	15 749	5110	32.45 (31.72-33.18)
55-64	11 285	3542	31.39 (30.53-32.24)
≥65	2746	732	26.66 (25.00-28.31)
Sex
Male	33 644	11 915	35.41 (34.90-35.93)	<.001
Female	24 203	5819	24.04 (23.50-24.58)
Insurance plan
Preferred provider organization	31 126	9454	30.37 (29.86-30.88)	<.001
Health maintenance organization	14 044	4679	33.32 (32.54-34.10)
Other	12 677	3601	28.41 (27.62-29.19)
Region
Northeast	14 131	3968	28.08 (27.34-28.82)	<.001
North Central	6556	2110	32.18 (31.05-33.32)
South	17 381	5765	33.17 (32.47-33.87)
West	19 779	5891	29.78 (29.15-30.42)
Type of clinician
Primary care physician	20 937	4885	23.33 (22.76-23.90)	<.001
Gastrointestinal or infectious disease specialist	27 866	9931	35.64 (35.08-36.20)
Other	9044	2918	32.26 (31.30-33.23)
Out-of-pocket expense
Quartile 1 (low)	16 852	5700	33.82 (33.11-34.54)	<.001
Quartile 2	14 358	3253	22.66 (21.97-23.34)
Quartile 3	13 643	4202	30.80 (30.03-31.57)
Quartile 4 (high)	12 994	4579	35.24 (34.42-36.06)
Liver disease severity
Noncirrhosis	52 853	15 854	30.00 (29.61-30.39)	<.001
Cirrhosis	3964	1379	34.79 (33.31-36.27)
Hepatocellular carcinoma	1030	501	48.64 (45.59-51.69)

Abbreviation: CHB, chronic hepatitis B.

^aBased on 2 outpatient encounters in the Truven database.